IDEAYA Biosciences (IDYA) Net Equity Issued and Repurchased (2018 - 2026)

IDEAYA Biosciences has reported Net Equity Issued and Repurchased for 8 years, with the latest figure at $25.0 million in Q1 2025.

• Quarterly Net Equity Issued and Repurchased fell 92.73% year-over-year to $25.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $25.0 million (down 90.89% YoY) and the FY2025 annual result came in at $25.0 million, down 90.89% from the prior year.
• Net Equity Issued and Repurchased rose to $25.0 million in Q1 2025 per IDYA's latest filing, from -$105.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $379.9 million in Q3 2024 and troughed at -$343.6 million in Q2 2024.
• A 5-year average of $40.1 million and a median of $15.4 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 152687.95% in 2024, down 182.77% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $28.7 million in 2021, then slumped by 101.31% to -$375000.0 in 2022, then surged by 34119.73% to $127.6 million in 2023, then plunged by 182.77% to -$105.6 million in 2024, then soared by 123.68% to $25.0 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $25.0 million, -$105.6 million, and $379.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.